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Abstract Specific IgE (slgE) for cow's milk proteins (CMP) 
have been reported to be present in blood sera of exclusively 
breast-fed infants. The aim of this study was to find whether the 
presence of slgE to human milk proteins in the sera of exclusively 
breast-fed infants could explain the apparent detection of slgE to 
CMP in infants that were never previously in contact with cow's 
milk. slgE for human milk whey proteins were found in the blood 
sera of atopic infants, and these slgE strongly cross-reacted with 
the corresponding CMP. In none of the sera examined were slgE 
to bovine pVlactoglobulin detected. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
In exclusively breast-fed infants the presence in the blood 
serum of specific IgE (slgE) to cow's milk proteins (CMP) has 
already been demonstrated [1]. The most frequently reported 
hypothesis to explain the presence of such slgE in exclusively 
breast-fed infants are: (i) sensitization to C M P can occur in 
utero [2,3]; (ii) sensitization to C M P , in particular (3-lactoglo-
bulin ((3-LG), can occur through ingestion by the mother of 
cow's milk with the diet and passage of C M P into breast milk 
[4-8]. 
However, the true passage of integer bovine (3-LG into 
human milk, at least in healthy subjects, has already been 
discussed in a previous paper [9]. Moreover, clinical studies 
on the usefulness of keeping the pregnant and lactating moth-
er's diet free from C M P in preventing cow's milk protein 
allergy (CMPA) have produced conflicting results, as reviewed 
by Fal th-Magnusson [10]. 
Other possible routes for sensitization to C M P in exclu-
sively breast-fed infants have been suggested, including inad-
vertent neonatal supplementation of cow's milk-based formu-
la, sensitization by inhaling [11] or through contamination of 
hands or household objects [8]. 
To explain the sensitization to C M P in exclusively breast-
fed infants, a synthesis of slgE primitively directed against 
human milk proteins that may cross-react with the C M P 
has never been considered. 
This study shows that slgE for human milk whey proteins is 
present in the blood serum of atopic infants, and that these 
slgE strongly cross-react with the corresponding C M P . 
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2. Materials and methods 
2.1. Subjects 
Six breast-fed infants aged between 1 and 9 months with atopic 
dermatitis diagnosed as indicated by Hanifin and Rajika [12] were 
examined. 
All infants tested positive for CMP at skin prick test (SPT, Neo 
Abello-Madrid-Spain) and slgE (chemiluminescence Magic Lite SQ-
CIBA CORNIG). As control, two healthy infants with negative per-
sonal and family history for atopy, and with both SPT and slgE 
negative for CMP, were examined. As IgE positive control, an infant 
with high total IgE level, but without slgE to milk proteins, was also 
examined. Individual blood samples were centrifuged (3000 rpm, 
10 min) and the sera obtained were divided into aliquots and stored 
at -20°C until use. 
2.2. Specimens 
Human milk samples were from two different pools of mature hu-
man milk, taken from four mothers on milk-rich diet ( > 500 ml/day 
plus free intake of milk derivatives) and from four mothers on a 
CMP-free diet. In the latter, care was taken to verify that they com-
pletely avoided cow's milk and its derivatives including ready-made 
food products or mixed foods that may contain small traces of CMP. 
The samples were taken after the mothers had followed the diet for 
2-4 weeks. Breast milk was always collected in the morning, 2 h after 
last meal ingestion, into sterile monouse tubes using an electric breast 
pump. Human milk samples were pooled and centrifuged (3000 rpm, 
30 min, 20°C). The skimmed milk was then submitted to ultracen-
trifugation (189000Xg, 120 min, 4°C) to separate casein (pellet) and 
residual lipids (top) from the clear solution (whey). 
Informed consent was obtained from parents of all infants and 
from donor mothers, after a full explanation of the procedures. 
Cow's whey proteins were obtained by ultracentrifugation 
(189 000 Xg, 120 min, 4°C) of skimmed milk. 
2.3. Sodium dodecylsulfate-polyacrylamide gel electrophoresis 
Milk samples were separated by sodium dodecylsulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) on Phast Gel-Gradient 8-25 
gels (Pharmacia) as described by Laemmli [13]. 
2.4. Western blotting 
Western blotting was carried out onto ProBlott membranes (Ap-
plied Biosystems) using a 25 mM Tris, 192 mM glycine, pH 8.3, 
transfer buffer. Complete transfer was achieved at 20 V, 25 mA, 
1 W, 5 Vh, 15°C, for 1 h. 
2.5. Immunostaining 
The blotted membranes were incubated overnight at room temper-
ature with individual serum diluted 1:10 with Tris-buffered saline 
(TBS). A second incubation was then done with an anti-human IgE, 
(e-chain specific) peroxidase conjugate (Sigma) diluted 1:1000 with 
TBS, polyclonal antibody. Color was developed in the presence of 
H 2 0 2 with 3-3'-diaminobenzidine as substrate. All the washing steps 
used TBS containing 0.2% Tween 20. 
2.6. Cross-inhibition 
A pool of sera of atopic infants sensitized to CMP was divided into 
aliquots and pre-incubated overnight at room temperature with 100, 
250 and 1000 u.1 of either denatured bovine milk whey or human milk 
whey proteins. The proteins were denatured by boiling the whey sam-
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Fig. 1. SDS-PAGE and Western blotting of cow's milk (whey) proteins. Molecular size standards (in kDa) are indicated at the left. A: Lane 1: 
Coomassie Blue staining of cow's whey proteins after SDS-PAGE and Western blotting. B: Immunostaining of human IgE specific to cow's 
milk (whey) proteins. Lanes 1-6: cow's milk protein that had bound to IgE from six individual atopic infants. Lane 7: serum from a healthy 
infant with negative personal and family history for atopy and with STP and slgE to CMP negative. 
pies for 5 min. in the presence of 1% SDS and 2% B-mercaptoethanol. 
The pre-incubated sera were then incubated with human (H) and 
bovine (B) milk whey samples after SDS-PAGE and Western blotting, 
following the protocol given above for immunoblotting. 
2.7. Sequencing 
Sequence determinations were carried out after SDS-PAGE and 
Western blotting on ProBlott membranes, on a gas-phase Applied 
Biosystems Model 470A Protein Sequencer. 
3. Results 
The immunostaining of slgE to CMP for each of the six 
atopic infants under investigation is in Fig. 1. The six patterns 
are rather similar, with only small quantitative differences. 
Bovine serum albumin, P-casein, lactoferrin and a-lactalbu-
min, in that order, were recognized as the most reactive 
CMP. None of the subjects showed slgE to bovine (3-LG. 
Fig. 2A shows the SDS-PAGE Coomassie Blue staining of 
human milk samples from mothers on bovine milk-rich and 
milk-free diets. No significant differences are visible between 
the two patterns. Fig. 2B shows the immunostaining of slgE 
of each infant serum reacting against human milk protein 
from the bovine milk-rich diet and milk-free diet pools. For 
each subject the IgE reactivity towards the human milk pro-
teins in the milk-rich diet pool was almost identical to that 
towards those in milk-free diet pool. By comparison with the 
SDS-PAGE Coomassie Blue staining of the human milk pro-
teins shown in Fig. 2A, human lactoferrin was identified as 
the most reactive protein against the serum IgE of each sub-
ject, followed by serum albumin, p-casein and a-lactalbumin 
in that order. 
Fig. 3 shows the result of competitive inhibition of IgE 
binding. Inhibition of IgE binding to CMP (Fig. 3A) or to 
human milk protein (Fig. 3B) appears to be correlated to the 
amount of denatured bovine or human whey added in the 
pool of human sera (dose-dependent inhibition). No inhibi-
tion of IgE binding to either human or bovine milk proteins 
was seen when incubation was done with either native (not 
denatured) bovine or human whey. 
When sera from healthy subjects and from a subject 
with high total serum IgE not specific for milk proteins 
were used as first antibody solution in the immunoblotting 
experiments, no slgE to either CMP or human milk proteins 
were detected. 
When cow's milk was suspended from the maternal diet 
and, at the same time, environmental precautionary measures 
were introduced, clinical observations revealed a marked re-
gression of clinical symptoms in all infants. Subsequent direct 
challenge by administering 10 ml of cow's milk to each infant 
was in all cases highly positive. 
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Fig. 2. SDS-PAGE and Western blotting of human milk whey proteins. Molecular size standards (in kDa) are indicated at the left. A: Lane 1: 
Coomassie Blue staining of human whey proteins from mothers on strictly controlled cow's milk-free diet. Lane 2: Coomassie Blue staining of 
human whey proteins from mothers on cow's milk-rich diet. Bands in lane 2 labeled with LT, HSA, B-CAS, and a-LA were identified by 
N-terminal sequence analysis as human lactoferrin, serum albumin, P-casein and a-lactalbumin, respectively. B: Lanes 1-3: human milk 
samples from mothers on cow's milk-rich diet (R) and strictly controlled cow's milk-free diet (F) were incubated with the sera three atopic in-
fants corresponding to Lanes 1, 3, 6 in Fig. 1, after SDS-PAGE and Western blotting. 
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Fig. 3. Competitive inhibition of IgE binding. A: Pool of sera of 
atopic infants sensitized to CMP was divided into aliquots and pre-
incubated overnight at room temperature with denaturated cow's 
milk proteins. The pre-incubated sera were then incubated with hu-
man (H) and bovine (B) milk whey samples after SDS-PAGE and 
Western blotting, following the protocol given above for immuno-
blotting (Fig. 1). Lane 1: Pre-incubation with dilution buffer (TBS) 
only; Lanes 2-4: Pre-incubation with 100, 250 and 1000 ul of dena-
turated cow's whey, respectively. B: The same as in (A), but pre-in-
cubation of atopic sera was with human whey. Lane 1: Pre-incuba-
tion with dilution buffer (TBS) only. Lanes 2-A: Pre-incubation 
with 100, 250 and 1000 ul of denaturated human whey, respectively. 
4. Discussion 
The dose-dependent inhibition of slgE to CMP binding to 
human milk proteins shown by denatured bovine whey pro-
teins and vice versa leads to the hypothesis of the presence of 
common epitopes (cross-reactivity) between bovine and hu-
man milk proteins. Lack of inhibition by native bovine and 
human whey proteins suggests that such epitopes are probably 
linear (continuous) and should lie in the internal part of the 
molecules. The rather high degree of homology between the 
primary structures of human milk proteins and the corre-
sponding bovine proteins (serum albumin, identity 76.6%; 
a-lactalbumin, identity 73.9%; lactoferrin, identity 69.5%; 
p-casein, identity 56.5%), is congruent with a possible cross-
reactivity towards specific antibodies, since IgE antibodies 
from birch profilin-allergic individuals have been reported to 
cross-react with human profilin where the identity between the 
two proteins is only 34% [14]. 
Although the reactivity of the IgE of each subject towards 
the human milk proteins from the totally bovine milk-free diet 
pool could be explained as a cross-reaction between slgE to 
CMP in subjects previously sensitized in utero and human 
milk proteins (but this sensitization should have occurred in 
six out of six subjects!), the constant absence of slgE to P-LG, 
the only bovine protein absent in human milk, leads rather to 
hypothesize the presence of slgE primitively directed against 
human milk proteins and cross-reacting with the homologous 
CMP. 
In high-risk atopic infants, if adverse reactions to CMP are 
mediated by the slgE primitively directed against human milk 
proteins, this could either occur at the first direct ingestion of 
CMP or because of the passage of small peptides of CMP in 
breast milk after the mother's ingestion of CMP with the diet. 
This might provide a rational explanation for Ghisolfi et al. 
[15] observation that CMPA, type I, appears at the first in-
troduction of CMP mainly in infants who were previously 
exclusively breast fed. 
The regression of clinical symptoms seen during the period 
when the infants were exclusively breast fed and were sub-
jected to protective maternal dietary regimen and environmen-
tal measures, together with the strong positive reaction to 
direct challenge with CMP, suggest that IgE circulating in 
the serum of the controlled atopic infants, able to cross-react 
in vitro with both CMP and human milk proteins, have no 
clinical significance against human milk, but only against 
cow's milk. 
We are at present engaged in some studies aimed at further 
clarifying the clinical significance of the cross-reactivity be-
tween human milk proteins and CMP, including one that 
will examine pairs comprising mother and breast-fed atopic 
infant. 
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